US · EXAS
Exact Sciences Corporation
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Madison, WI 53719
- Website
- exactsciences.com
Price · as of 2025-12-31
—
Market cap 19.73B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $67.94 | — |
| Intrinsic Value(DCF) | $42.52 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9.47 | $25.11 | $0.98 | $0.00 | $7.05 |
| 2012 | $10.95 | $25.77 | $0.73 | $0.00 | $0.00 |
| 2013 | $13.72 | $29.39 | $1.20 | $0.00 | $0.00 |
| 2014 | $24.04 | $33.47 | $2.14 | $0.00 | $57.37 |
| 2015 | $6.35 | $292.33 | $46.67 | $0.00 | $0.00 |
| 2016 | $21.37 | $45.44 | $42,904.69 | $0.00 | $0.00 |
| 2017 | $52.15 | $62.69 | $2,151,870.22 | $0.00 | $0.00 |
| 2018 | $85.37 | $63.09 | $1,210,551.37 | $0.00 | $0.00 |
| 2019 | $65.58 | $54.52 | $2,869.85 | $0.15 | $0.00 |
| 2020 | $128.46 | $76.07 | $46,020.31 | $0.00 | $0.00 |
| 2021 | $62.75 | $43.97 | $1,030.05 | $0.00 | $0.00 |
| 2022 | $61.99 | $37.99 | $80.34 | $0.00 | $0.00 |
| 2023 | $60.04 | $49.60 | $0.32 | $0.00 | $0.00 |
| 2024 | $47.06 | $32.52 | $0.00 | $0.00 | $0.00 |
| 2025 | $103.35 | $67.94 | $2.20 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Exact Sciences Corporation's (EXAS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $67.94
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$42.52
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| DOCS | Doximity, Inc. | $24.53 | 4.61B | +213% | +46% | -54% | +33% | 49.27 | 10.16 | 19.28 | 41.92 | 90.95 | 11.09 | 90.20% | 39.94% | 39.13% | 22.50% | 116.06% | 19.05% | 0.01 | — | 6.97 | 6.68 | -0.82 | 5417.00% | 1998.00% | 4961.00% | 2.43% | 1.75 | 160.49% | 0.00% | 0.00% | 2.14% | 44.30 | 37.84 | 17.69 | 38.45 |
| GH | Guardant Health, Inc. | $93.90 | 12.32B | -39% | -48% | — | — | -27.78 | -116.44 | 11.77 | -32.21 | — | -57.11 | 64.46% | -44.43% | -42.39% | 348.42% | -117.88% | -23.79% | -16.94 | -111.96 | 4.84 | 4.42 | -3.49 | -674.00% | 3288.00% | -1523.00% | -2.02% | -0.61 | -63.16% | 0.00% | 0.00% | 0.12% | -27.61 | -51.68 | 12.26 | 1.67 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| ROIV | Roivant Sciences Ltd. | $28.94 | 20.71B | +3% | -75% | -82% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
| VTRS | Viatris Inc. | $14.93 | 17.2B | +55% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
- CEO
- Kevin T. Conroy
- Employees
- 6.9K
- Beta
- 1.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($42.52 ÷ —) − 1 = — (DCF, example).